Key result
Direct oral anticoagulants are an effective therapy for treating left ventricular thrombi compared to warfarin.
Why the study?
DOAC therapy for left ventricular thrombi remains off-label due to a paucity of evidence, despite being guideline therapy in many hypercoagulable diseases.
Does direct oral anticoagulant (DOAC) therapy improve efficacy compared to warfarin in patients with left ventricular thrombi?
Does direct oral anticoagulant (DOAC) therapy improve efficacy compared to warfarin in patients with left ventricular thrombi?
This study evaluates the efficacy of DOACs versus warfarin for the off-label treatment of left ventricular thrombi.
May support off-label DOAC consideration in LVT; leaves open need for RCTs to confirm efficacy and safety.
Despite being guideline therapy in many hypercoagulable diseases, direct oral anticoagulant (DOAC) therapy in left ventricular thrombi (LVT) remains off-label due to a paucity of evidence. This study evaluated the efficacy of DOAC versus warfarin use for LVT. 264 patients with LVT on TTE or TEE
No takes yet. Share an insight, caveat, or question.
Yunis et al. (2020) studied this question. Direct oral anticoagulants are an effective therapy for treating left ventricular thrombi compared to warfarin.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: